GLP-1 receptor agonist (once-weekly)
A once-weekly injectable GLP-1 medication used to manage type 2 diabetes and, off-label, to support weight loss.
| Class / type | GLP-1 receptor agonist (once-weekly) |
|---|---|
| Category | Metabolic & Weight |
| Status (Jul 2026) | FDA-approved |
Mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. This lowers blood sugar and reduces appetite.
FDA-approved for glycemic control in type 2 diabetes and reducing major cardiovascular events; used off-label for weight management.
Improves blood sugar control and A1c, provides cardiovascular risk reduction, and produces modest weight loss with convenient once-weekly dosing.
Common side effects include nausea, vomiting, diarrhea, and reduced appetite; carries a boxed warning for thyroid C-cell tumors seen in rodents and risk of pancreatitis.
Users report appreciating the once-weekly schedule, steady appetite reduction, and meaningful A1c improvements.
FDA-approved: marketed as Trulicity (approved 2014) for type 2 diabetes and cardiovascular risk reduction.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.